Shu W, Wang J, Zhu X, Wang K, Cherepanoff S, Conway R
J Cancer. 2023; 14(18):3477-3495.
PMID: 38021158
PMC: 10647189.
DOI: 10.7150/jca.88446.
Delgado-Bellido D, Zamudio-Martinez E, Fernandez-Cortes M, Herrera-Campos A, Olmedo-Pelayo J, Jordan Perez C
Cell Death Dis. 2023; 14(2):135.
PMID: 36797281
PMC: 9935922.
DOI: 10.1038/s41419-023-05666-7.
Fernandez-Cortes M, Delgado-Bellido D, Bermudez-Jimenez E, Paramio J, OValle F, Vinckier S
J Pathol. 2022; 259(3):318-330.
PMID: 36484652
PMC: 10107856.
DOI: 10.1002/path.6043.
Zhang Y, Zhang B, Li Y, Dai Y, Li J, Li D
Front Med. 2022; 16(5):784-798.
PMID: 35997986
DOI: 10.1007/s11684-021-0911-0.
Uner O, Gandrakota N, Azarcon C, Grossniklaus H
Ann Eye Sci. 2022; 7.
PMID: 35350473
PMC: 8959478.
DOI: 10.21037/aes-21-30.
Relevance of BRAF Subcellular Localization and Its Interaction with and Mutations in Skin Melanoma.
Beleaua M, Jung I, Braicu C, Milutin D, Gurzu S
Int J Mol Sci. 2021; 22(21).
PMID: 34769348
PMC: 8584522.
DOI: 10.3390/ijms222111918.
TFPI2 Promotes Perivascular Migration in an Angiotropism Model of Melanoma.
Mo J, Zhao X, Wang W, Zhao N, Dong X, Zhang Y
Front Oncol. 2021; 11:662434.
PMID: 34249699
PMC: 8264799.
DOI: 10.3389/fonc.2021.662434.
The Role of Non-Coding RNAs in Uveal Melanoma.
Bande M, Fernandez-Diaz D, Fernandez-Marta B, Rodriguez-Vidal C, Lago-Baameiro N, Silva-Rodriguez P
Cancers (Basel). 2020; 12(10).
PMID: 33053887
PMC: 7600503.
DOI: 10.3390/cancers12102944.
Mouse models of uveal melanoma: Strengths, weaknesses, and future directions.
Richards J, Yoo J, Shin D, Odelberg S
Pigment Cell Melanoma Res. 2019; 33(2):264-278.
PMID: 31880399
PMC: 7065156.
DOI: 10.1111/pcmr.12853.
Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status.
Calderon-Aparicio A, Cornejo A, Orue A, Rieber M
Ecancermedicalscience. 2019; 13:890.
PMID: 30792807
PMC: 6369974.
DOI: 10.3332/ecancer.2019.890.
Short Tandem Repeat (STR) Profiles of Commonly Used Human Ocular Surface Cell Lines.
McDermott A, Baidouri H, Woodward A, Kam W, Liu Y, Chen X
Curr Eye Res. 2018; 43(9):1097-1101.
PMID: 29787296
PMC: 6590053.
DOI: 10.1080/02713683.2018.1480043.
Obstruction of BRAF transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth.
Rothman J, Surriga O, de Stanchina E, Vasudeva S, Schwartz G
Cancer Gene Ther. 2017; 24(9):401-408.
PMID: 28937091
DOI: 10.1038/cgt.2017.34.
Expression of Antimicrobial Peptides by Uveal and Cutaneous Melanoma Cells and Investigation of Their Role in Tumor Cell Migration and Vasculogenic Mimicry.
Manarang J, Otteson D, McDermott A
Curr Eye Res. 2017; 42(11):1474-1481.
PMID: 28910167
PMC: 6141659.
DOI: 10.1080/02713683.2017.1339806.
Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.
Kemp D, Pidich A, Larijani M, Jonas R, Lash E, Sato T
Oncotarget. 2017; 8(9):14428-14442.
PMID: 28129639
PMC: 5362416.
DOI: 10.18632/oncotarget.14803.
KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.
Cicenas J, Tamosaitis L, Kvederaviciute K, Tarvydas R, Staniute G, Kalyan K
Med Oncol. 2017; 34(2):26.
PMID: 28074351
DOI: 10.1007/s12032-016-0879-9.
Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?.
Lobo J, Pinto C, Freitas M, Pinheiro M, Vizcaino R, Oliva E
Virchows Arch. 2016; 470(3):347-352.
PMID: 27915441
DOI: 10.1007/s00428-016-2052-4.
Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
Orue A, Chavez V, Strasberg-Rieber M, Rieber M
BMC Cancer. 2016; 16(1):902.
PMID: 27863474
PMC: 5116131.
DOI: 10.1186/s12885-016-2930-9.
Animal Models of Uveal Melanoma: Methods, Applicability, and Limitations.
Stei M, Loeffler K, Holz F, Herwig M
Biomed Res Int. 2016; 2016:4521807.
PMID: 27366747
PMC: 4913058.
DOI: 10.1155/2016/4521807.
Standard melanoma-associated markers do not identify the MM127 metastatic melanoma cell line.
Haridas P, McGovern J, Kashyap A, McElwain D, Simpson M
Sci Rep. 2016; 6:24569.
PMID: 27087056
PMC: 4834532.
DOI: 10.1038/srep24569.
CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux.
Davar D, Kirkwood J
Clin Cancer Res. 2015; 21(24):5412-4.
PMID: 26672083
PMC: 4683414.
DOI: 10.1158/1078-0432.CCR-14-3132.
